In This Section

Postdoctoral Opportunities at Fels Cancer Institute for Personalized Medicine

Dr. Jonathan Soboloff

Fels Institute (Temple University, Philadelphia, PA) has several openings for a postdoctoral position in Cancer related fields. PIs with openings include:

  • Dr. Jonathan Soboloff (Modulation of Ca2+ signaling by STIM1)

I am interested in recruiting a new postdoctoral fellow to study numerous aspects of STIM-dependent Ca2+ signaling. The ideal candidate will have a recent PhD, at least 1 first author publication in a mid- to high-impact journal. Our interests include fundamental mechanisms regulating the generation of Ca2+ signals and their relevance to multiple aspects of immunology, cancer and bone physiology. However, as this lab has just received new funding to investigate T cell activation, the new lab member would be expected to work primarily in this area. Research techniques used in the lab include advanced microscopy approaches, Western analysis, ChIP, qPCR and general molecular biology.

The position is fulltime, with the expectation that the fellow will be independently motivated. As a postdoctoral fellow, the primary duty will be to complete scientific experiments towards the preparation of published works, although I will also support career development as appropriate and needed. The ideal candidate will keep up with relevant literature, contribute to scientific writing and present our research at international conferences with my full support.

Finally, as a senior lab member, I anticipate that the fellow will contribute to the training of junior lab members. When significant, these contributions will be recognized with authorship on publications.

US citizens/green card holders will have opportunities for external funding and will receive special consideration.

Please submit application electronically with curriculum vitae, a cover letter, and the names/phone numbers/emails of three people who can provide letters of reference to: Dr. Jonathan Soboloff, Fels Cancer Institute for Personalized Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA. Email:

Dr. Tomasz Skorski

Postdoctoral positions supported by NIH/NCI grants are immediately available in the laboratory of Dr. Tomasz Skorski, the Director of Fels Cancer Institute for Personalized Medicine at Temple University School of Medicine, Philadelphia. The research is focused on: (1) determination the mechanistic aspects of how mutations driving leukemias modulate DNA damage response, (2) identification of mutation patterns in leukemias, which determine the sensitivity of malignant cells to specific DNA repair inhibitors, and (3) testing new drugs targeting DNA damage response in single cells/clones. Our overall goal is to develop biomarkers that predict tumor response to novel DNA repair inhibitors combined with standard DNA damaging agents and to understand molecular mechanisms. Research involves molecular biology of DNA repair, testing novel drugs, mouse models of cancer, bioinformatics, and extensive mammalian tissue culture. Candidates must be enthusiastic to commit necessary effort required to develop a successful and highly productive research career. Candidates must be residing in the U.S.

Candidates interested in the position should send curriculum vitae, a brief description of research experience, and names of three references to Dr. Tomasz Skorski (Email:

Dr. Christian Hurtz

Postdoctoral positions are available in the laboratory of Dr. Christian Hurtz. The Hurtz lab is NIH/NCI funded and conducts basic and translational research with a focus on identifying novel treatment strategies for patients with acute lymphoblastic leukemia (ALL).

The available postdoctoral research projects focus on:

1) Elucidate oncogene independent signaling activation and determine alternative treatment strategies for patients with high-risk Philadelphia chromosome-like ALL.

2) Validate if inhibition of STAT5 signaling results in V(D)J mediated DNA-damage and determine the importance of DNA repair mechanisms to induce drug resistance.  

3) Determine if forced pharmacologic hyperactivation of B cell receptor signaling pathways results in negative selection of malignant cells and validate if signaling hyperactivation is a feasible therapy option for KMT2A-R ALL patients. 

Highly motivated applicants with a PhD degree in cancer biology, immunology, molecular biology, or a related area are encouraged to apply. Practical experience with molecular and cellular biology techniques and animal models is required as well as at least 1 first author publication. Preference will be given to recently graduated candidates with a strong career motivation who resides in the US. Competitive stipend and a generous benefits package commensurate with experience will be provided.

To learn more about our research please visit:

Please submit application electronically with curriculum vitae, a cover letter with a brief description of research experience, and the names/phone number/emails of three references to:

Dr. Christian Hurtz
Fels Cancer Institute for Personalized Medicine
Lewis Katz School of Medicine at Temple University
Philadelphia, PA 19140